CONTENTS A. B. C. D. E. II. A. B. V. eee ee 8 © © © © 0 6 tee ee ee ee ee we ee ew) ee we we et ww wh ww tlw tl © © © © © © © © © @ ew te ew tt @ © ew we eo ew tw et te et Background . . The Accident . 2. . 1 2. 6 6 © 2 6 6 ee 2 6 ee © 8 ew we ee oe ew wt ww ww ee ee ww we we . 2. 2. 6 6 2 6 ee ew we we we ew 6 1 1 0 ee ew ee we we 6 © © «© we 1. 2. Early Radiation Residual Radiation . 1... Data Evaluation . 2. .... 6 ew ew ew ew 2. © ©» ee we th we ee wt we ee ww te ew a Background . 2. 2. 6 6 ee ew ee 1. 2 Methods . 2. 1. 6 6 0 6 ee Results and Discussion . 2. Background . Methods . 2. Results 2. 2. Discussion. AGING, . 2. 2 . 1 6 6 6 2 2 .. . ww eh we ew tw ww te eh we 2. 6 ew 6 ee ww et 6 ee ee ew et wh ew wt 2. 2 1 we © 7 6 6 © ee we ew we ew we ew we ew we ew we we soe we © © ee eo ee ee ee ee ee ee ww we we et 16 16 16 18 26 re 32 he ee ee 32 te ee 10 11 26 26 28 28 Chromosome and Genetic Studies . .. 1... 6 ee ee te ew ee eee l. Chromosome Studies ..... ye ee ee ee ew 2. Isoleucine Misincorporation inn Hemoglobin A of Marshallese o 3. Detection of Mutant Proteins... oo . . eee 1. 2. 1. ee ee GE te ee te ee C. . . we we wt we Aging Studies Immunological Studies 6 we wt tw ww we we we we ee ee we we ww ew we wee we wt ww wt a ee IMMUNOLOGICAL, " CHROMOSOME, " AND " CENETIC "STUDIES 2... te we we A. ee 32 33 33 33 35 PARASITOLOGIC SURVEYS AND SUPPRESSIVE ANTI- HELMINTH TREATMENT ON A. Background . . 1977-1979 . 2. 1. 1 1 0 2 ew we we 1. 2 1 6 0 ee wee ee ew we we te we te we te ee te ee 36 wt 36 B. C. D. Methods . 2. 2. 6 2 6 ee ew ew Results and Discussion . . 1. 1 Conclusions . . 6. 6 1 ew ee DIABETES SURVEY . 2... NEOPLASIA (NON-THYROID) 1 . 6 2. ew we ee we ww 6 ee ew we ee ee te he wh ww we et et ew wh te ew hh he 36 38 41 A. Malignancies 2... 6 ee ww ee ee te ee we te te 47 C. Pituitary Tumor . 1. 1 1 we ew ee ee ee ew et ht te we 49 . . 1... 1 2 we ee ew ee et wt et B. IX. ht th wt Background . 2. 2 6 6 6 6 ee ww we ee ee we ew te Methods . . 2. 2 2 2 oe 6 ee ew ww ew we we ww wt wt we l. Procedures . 2. 6. 6 6 2 6 © ee eo ew ww we we we tw wt we 2. Control Populations . . 2. 6 6 2 2 ee ee we ew ee we el Results ..... a RONGELAP AND UTIRIK, VII. VIII. 6 6 Early Clinical Effects . 2. 2. 6 ee ee ee ww ee ee ee ee Dosimetric Evaluation . 2. 2. 2. 6 2 6 ee ee te we te we ee GROWTH AND DEVELOPMENT A. B. C. D. B. VI. ee 6 8 2. 6 2 6 HEMATOLOGIC OBSERVATIONS A. B. C. IV. 6 0 2. 6 GENERAL MEDICAL SURVEYS C. III. 6 «© . 2. re MOOMnAINIUNW WN ee K I. DEDICATION . . 0. PREFACE . 2. 6 6 ACKNOWLEDGMENTS INTRODUCTION . 2. Benign Tumors . . 2. THYROID ABNORMALITIES A. we 1. 6 we ee ee ew ee te wt ee 1. 0. 6 6 1 ew ee we ew we Background (Chronology of Developments) - xii - tt et wt we et we th te ete we we ew ee ee tt wt ee .... 5.6.1 se eee 43 47 48 53 53